We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors.

Shelley Force Aldred, Ph.D., is a co-founder, investor, and CEO of Rondo Therapeutics. Prior to starting Rondo, Shelley was a member of Teneobio’s founding team where she led preclinical development for the company’s CD3 T-cell engager platform which ultimately generated $1.5B in up-front payments through partnerships and an acquisition by Amgen.  Early in her career, Shelley developed a passion for starting companies when she co-founded SwitchGear Genomics and later sold it to Active Motif. Shelley earned a Ph.D. in Genetics from Stanford where she continues to be involved as an advisor for Stanford’s SPARK translational medicine program and as a member of the Board of Governors for the Stanford Medicine Alumni Association.

Nathan is a co-founder, investor, and board member of Rondo Therapeutics and currently serves as President and CSO. Prior to starting Rondo, Nathan was Chief Technology Officer at Teneobio where he played a key role in starting the company and led the team that was responsible for lead discovery, lead optimization, and development of the T-cell engager platform that was acquired in 2021. Prior to Teneobio, Nathan was a co-founder and CEO of SwitchGear Genomics, venture-backed functional genomics platform company that was acquired in 2013. Earlier in his career, Nathan served as the Technical Director of the Stanford ENCODE project and received his Ph.D from Stanford University. Nathan also serves on the Board of Governors for the Stanford Medicine Alumni Association. Nathan has published over 30 peer-reviewed papers and is an inventor on over 15 patents.

Katherine is Chief Development Officer at Rondo Therapeutics and brings over a decade of experience advancing antibody-based therapeutics to the clinic. Previously, she was the Vice President of Discovery at Amgen and Teneobio, where she led successful Oncology Research teams, advancing clinical candidates that resulted in 4 IND approvals in less than 6 years. She joined Teneobio when the company started lab operations in 2015, playing a key role in both building and managing a high-throughput antibody discovery platform. Prior to her work at Teneobio, she was a research scientist at Active Motif and SwitchGear Genomics where she focused her efforts on developing a functional genomics platform for small molecule screening. Katherine also serves on the Board of Directors for The Antibody Society. Katherine holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She has presented in numerous national and international conferences, has multiple peer-reviewed publications and is an inventor on more than 15 patents.

Thomas serves as Chief Medical Officer at Rondo Therapeutics and brings over 25 years of oncology clinical research and development experience.  Prior to starting at Rondo, Thomas was VP of Clinical Development at IGM Biosciences, where he led several T cell engager programs in heme and solid tumor indications.  Prior to IGM, Thomas was VP of Clinical Development and Medical Affairs at Adaptive Biotechnologies. Earlier in his career, he led several ADC programs in heme indications, including clinical lead for a successful sBLA for Adcetris in peripheral T cell lymphomas. Thomas did his clinical and research fellowship at Fred Hutchinson Cancer Center and Seattle Children's Hospital.

Meghana is VP of business development, leading outreach and partnering efforts for Rondo Therapeutics. She is an experienced business development professional, with a science-centric approach to transact biopharma partnerships. Meghana joined Rondo from Johnson & Johnson Innovation, where she served as Director of Early Innovation Partnering for Oncology. There she led end-to-end deal flow, including sourcing, due diligence, and negotiating research collaboration and licensing deals in immuno-oncology and hematology. Prior to Johnson & Johnson, Meghana was a management consultant for Syneos Health, building strategic plans for Medical Affairs oncology teams at mid and large pharma. Meghana holds a PhD from Vanderbilt University in Cancer Biology.

Starlynn leads the pre-clinical biology group at Rondo Therapeutics, an IO-focused biopharmaceutical company developing innovative bispecific therapeutic antibodies for treating solid tumors. She has worked in discovery and preclinical development in the fields of oncology and immunology at several biotechnology start-up companies, including Frontier Medicines and Caribou Biosciences. As a founding member of the pre-clinical biology team at Teneobio, a highly successful multi-specific therapeutic antibody company, she contributed to several bispecific antibody programs currently in clinical trials. Starlynn completed her PhD in the lab of Charles Craik at UCSF, where she studied novel viral and fungal host-pathogen interactions.

Udaya is Director of translational biology at Rondo Therapeutics. Prior to Rondo, Udaya was a Principal Scientist at Amgen following Amgen’s acquisition of Teneobio in 2021. At both Amgen and Teneobio, Udaya has played a key role in multiple heme-oncology programs taking T cell engager molecules from lead optimization through first-in-human studies, including three programs that are in active clinical trials. Prior to Teneobio, Udaya was a post-doc at MedImmune/Astrazeneca working on mechanisms of oncolytic virotherapy. Udaya received her PhD in microbiology and molecular genetics from Emory University and identified novel signaling pathways driving the pathogenesis of an oncogenic viral protein.